University of Washington and Fred Hutchinson Cancer Research Center, 825 Eastlake Ave E, Mailstop G3-200, Seattle, WA 98109, USA.
Best Pract Res Clin Haematol. 2013 Sep;26(3):261-8. doi: 10.1016/j.beha.2013.10.006. Epub 2013 Oct 16.
It seems clear that immunoconjugates, the combinations of antibodies with toxins, will play a role in therapy of acute myeloid leukemia (AML). It is also clear that sole emphasis on an average trial result is misplaced in AML, as the example of gentuzumab ozogamicin illustrates. Gemtuzumab added to chemotherapy can improve survival in many patients with newly diagnosed disease. The future of immunoconjugates, however, may rest on further defining the relation between CD33 and the AML stem cell and its importance in therapy. Three immunoconjugates with the cell surface antigens CD33, CD45, and CD30 will be reviewed here.
很明显，免疫偶联物（抗体与毒素的结合物）将在急性髓细胞白血病（AML）的治疗中发挥作用。同样清楚的是，在 AML 中，仅仅强调平均试验结果是不合适的，因为吉妥珠单抗奥佐米星就是一个例子。在化疗中加入吉妥珠单抗可以改善许多新诊断疾病患者的生存率。然而，免疫偶联物的未来可能取决于进一步确定 CD33 与 AML 干细胞之间的关系及其在治疗中的重要性。本文将对三种具有细胞表面抗原 CD33、CD45 和 CD30 的免疫偶联物进行综述。
